{
    "root": "56badfc0-fbd5-4810-a66b-40b8843c94ae",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Esomeprazole Magnesium",
        "suffix": {
            "text": "for delayed-release oral suspension"
        }
    },
    "value": "20250311",
    "ingredients": [
        {
            "name": "ESOMEPRAZOLE MAGNESIUM",
            "code": "R6DXU4WAY9"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "CROSPOVIDONE (35 .MU.M)",
            "code": "40UAA97IT9"
        },
        {
            "name": "DEXTROSE MONOHYDRATE",
            "code": "LX22YL083G"
        },
        {
            "name": "ETHYLCELLULOSE, UNSPECIFIED",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "GLYCERYL MONOSTEARATE",
            "code": "230OU9XXE4"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (110000 WAMW)",
            "code": "5Y0974F5PW"
        },
        {
            "name": "MAGNESIUM OXIDE",
            "code": "3A3U0GI71G"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POVIDONE K90",
            "code": "RDH86HJV5Z"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        }
    ],
    "indications": "esomeprazole magnesium delayed-release oral suspension proton pump inhibitor ( ppi ) . esomeprazole magnesium delayed-release oral suspension indicated : short-term treatment healing erosive esophagitis ( ee ) adults pediatric patients 12 years 17 years age . ( 1.1 ) maintenance healing ee adults . ( 1.2 ) short-term treatment heartburn symptoms associated gerd adults pediatric patients 12 years 17 years age . ( 1.3 ) risk reduction nonsteroidal anti-inflammatory drugs ( nsaid ) -associated gastric ulcer adults risk developing gastric ulcers due age ( 60 years older ) and/or documented history gastric ulcers . ( 1.4 ) helicobacter pylori eradication adult patients reduce risk duodenal ulcer recurrence combination amoxicillin clarithromycin . ( 1.5 ) long-term treatment pathological hypersecretory conditions , including zollinger-ellison syndrome adults . ( 1.6 ) esomeprazole magnesium delayed-release oral suspension indicated : short-term treatment healing ee pediatric patients 1 year 11 years age ee due acid-mediated gerd pediatric patients 1 month less 1 year age . ( 1.1 ) short-term treatment heartburn symptoms associated gerd pediatric patients 1 year 11 years age . ( 1.3 )",
    "contraindications": "population recommended adult ( 2.1 ) pediatric ( 2.2 ) healing ee ( 1 year older ) ee due acid-mediated gerd ( 1 month less 1 year ) adults 20 mg 40 mg 1 daily 4 8 weeks ; patients may require additional 4 8 weeks 12 years 17 years 20 mg 40 mg 1 daily 4 8 weeks 1 month 11 years full prescribing information weight-based dosing duration treatment ( 2.2 ) maintenance healing ee adults 20 mg daily . controlled extend beyond 6 months treatment symptomatic gerd adults 20 mg daily daily 4 weeks patients may require additional 4 weeks 12 years 17 years 20 mg daily 4 weeks 1 year 11 years 10 mg daily 8 weeks risk reduction nsaid-associated gastric ulcer adults 20 mg 40 mg 1 daily 6 months 2 h. pylori eradication reduce risk duodenal ulcer recurrence adults esomeprazole magnesium 40 mg 1 daily 10 days amoxicillin 1,000 mg twice daily 10 days 3 clarithromycin 500 mg twice daily 10 days 3 pathological hypersecretory conditions including zollinger-ellison syndrome adults starting 40 mg twice daily 4 ( varies individual patient ) long clinically indicated . 1 maximum 20 mg daily recommended patients severe liver impairment ( child-pugh class c ) . 2 controlled extend beyond 6 months . 3 refer amoxicillin clarithromycin prescribing information adjustments elderly renally-impaired patients . 4 starting 20 mg twice daily recommended patients severe liver impairment ( child-pugh class c ) . preparation information mix packets water create oral suspension . ( 2.3 ) oral suspension administered nasogastric gastric tube . ( 2.3 )",
    "warningsAndPrecautions": "esomeprazole magnesium delayed-release oral suspension supplied unit dose child-resistant packet containing light yellow , free flow granules , consisting off-white cream esomeprazole pellets pale yellow inactive granules . esomeprazole magnesium delayed-release oral suspension unit dose packets supplied follows : unit dose packages 30 : 10 mg esomeprazole packets ndc 13668-548-94 store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) . [ usp controlled room temperature ] .",
    "adverseReactions": "esomeprazole magnesium delayed-release oral suspension contraindicated patients known hypersensitivity substituted benzimidazoles component formulation . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 ) , ( 6.2 ) ] . information amoxicillin clarithromycin , indicated combination esomeprazole magnesium delayed-release oral suspension h. pylori eradication reduce risk duodenal ulcer recurrence , refer section respective prescribing information . proton pump inhibitors ( ppis ) , including esomeprazole magnesium , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] .",
    "indications_original": "Esomeprazole magnesium for delayed-release oral suspension is a proton pump inhibitor (PPI). Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 )",
    "contraindications_original": "Population Recommended Adult ( 2.1 ) and Pediatric Dosage ( 2.2 ) Healing of EE (1 year and older) EE due to Acid-Mediated GERD (1 month to less than 1 year) Adults 20 mg or 40 mg 1 once daily for 4 to 8 weeks; some patients may require an additional 4 to 8 weeks 12 years to 17 years 20 mg or 40 mg 1 once daily for 4 to 8 weeks 1 month to 11 years see full prescribing information for weight-based dosing and duration of treatment ( 2.2 ) Maintenance of Healing of EE Adults 20 mg once daily. Controlled studies do not extend beyond 6 months Treatment of Symptomatic GERD Adults 20 mg once daily once daily for 4 weeks some patients may require an additional 4 weeks 12 years to 17 years 20 mg once daily for 4 weeks 1 year to 11 years 10 mg once daily for up to 8 weeks Risk Reduction of NSAID-Associated Gastric Ulcer Adults 20 mg or 40 mg 1 once daily for up to 6 months 2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Adults Esomeprazole magnesium 40 mg 1 once daily for 10 days Amoxicillin 1,000 mg twice daily for 10 days 3 Clarithromycin 500 mg twice daily for 10 days 3 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome Adults Starting dosage is 40 mg twice daily 4 (varies with the individual patient) as long as clinically indicated. 1 A maximum dosage of 20 mg once daily is recommended for patients with severe liver impairment (Child-Pugh Class C). 2 Controlled studies do not extend beyond 6 months. 3 Refer to the amoxicillin and clarithromycin prescribing information for dosage adjustments in elderly and renally-impaired patients. 4 A starting dosage of 20 mg twice daily is recommended for patients with severe liver impairment (Child-Pugh Class C). Preparation and Administration Information Mix packets with water to create an oral suspension. ( 2.3 ) Oral suspension can be administered through a nasogastric or gastric tube. ( 2.3 )",
    "warningsAndPrecautions_original": "Esomeprazole Magnesium For Delayed-Release Oral Suspension is supplied as a unit dose child-resistant packet containing a light yellow, free flow granules, consisting of off-white to cream esomeprazole pellets and pale yellow inactive granules. Esomeprazole magnesium for delayed-release oral suspension unit dose packets are supplied as follows:\n                  Unit dose packages of 30: 10 mg\u00a0esomeprazole packets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 13668-548-94\n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F).[See USP Controlled Room Temperature].",
    "adverseReactions_original": "Esomeprazole magnesium for delayed-release oral suspension is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.2), Adverse Reactions (6.2)].\n                     For information about contraindications of amoxicillin and clarithromycin, indicated in combination with\u00a0esomeprazole magnesium for delayed-release oral suspension for H. pylori eradication to reduce the risk of duodenal ulcer recurrence, refer to the Contraindications section of the respective prescribing information.\n                     Proton pump inhibitors (PPIs), including esomeprazole magnesium, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7)]."
}